请输入关键字
请输入关键字
订购
*国家
中国
美国
中国香港
中国澳门
中国台湾
阿尔巴尼亚
阿尔及利亚
阿根廷
阿拉伯联合酋长国
阿鲁巴
阿曼
阿塞拜疆
阿森松岛
埃及
埃塞俄比亚
爱尔兰
爱沙尼亚
安道尔
安哥拉
安圭拉
安提瓜和巴布达
奥地利
奥兰群岛
澳大利亚
巴巴多斯
巴布亚新几内亚
巴哈马
巴基斯坦
巴拉圭
巴勒斯坦领土
巴林
巴拿马
巴西
白俄罗斯
百慕大
保加利亚
北马里亚纳群岛
贝宁
比利时
冰岛
波多黎各
波兰
波斯尼亚和黑塞哥维那
玻利维亚
伯利兹
博茨瓦纳
不丹
布基纳法索
布隆迪
朝鲜
赤道几内亚
丹麦
德国
迪戈加西亚岛
东帝汶
多哥
多米尼加共和国
多米尼克
俄罗斯
厄瓜多尔
厄立特里亚
法国
法罗群岛
法属波利尼西亚
法属圭亚那
法属南部领地
梵蒂冈
菲律宾
斐济
芬兰
佛得角
福克兰群岛
冈比亚
刚果(布)
刚果(金)
哥伦比亚
哥斯达黎加
格恩西岛
格林纳达
格陵兰
格鲁吉亚
古巴
瓜德罗普
关岛
圭亚那
哈萨克斯坦
海地
韩国
荷兰
荷属加勒比区
荷属圣马丁
黑山
洪都拉斯
基里巴斯
吉布提
吉尔吉斯斯坦
几内亚
几内亚比绍
加拿大
加纳
加纳利群岛
加蓬
柬埔寨
捷克
津巴布韦
喀麦隆
卡塔尔
开曼群岛
科科斯(基林)群岛
科摩罗
科索沃
科特迪瓦
科威特
克罗地亚
肯尼亚
库克群岛
库拉索
拉脱维亚
莱索托
老挝
黎巴嫩
立陶宛
利比里亚
利比亚
联合国
列支敦士登
留尼汪
卢森堡
卢旺达
罗马尼亚
马达加斯加
马恩岛
马尔代夫
马耳他
马拉维
马来西亚
马里
马其顿
马绍尔群岛
马提尼克
马约特
毛里求斯
毛里塔尼亚
美国本土外小岛屿
美属萨摩亚
美属维尔京群岛
蒙古
蒙特塞拉特
孟加拉国
秘鲁
密克罗尼西亚
缅甸
摩尔多瓦
摩洛哥
摩纳哥
莫桑比克
墨西哥
纳米比亚
南非
南极洲
南乔治亚和南桑威奇群岛
南苏丹
瑙鲁
尼加拉瓜
尼泊尔
尼日尔
尼日利亚
纽埃
挪威
诺福克岛
帕劳
皮特凯恩群岛
葡萄牙
日本
瑞典
瑞士
萨尔瓦多
萨摩亚
塞尔维亚
塞拉利昂
塞内加尔
塞浦路斯
塞舌尔
沙特阿拉伯
圣巴泰勒米
圣诞岛
圣多美和普林西比
圣赫勒拿
圣基茨和尼维斯
圣卢西亚
圣马丁岛
圣马力诺
圣皮埃尔和密克隆群岛
圣文森特和格林纳丁斯
斯里兰卡
斯洛伐克
斯洛文尼亚
斯瓦尔巴和扬马延
斯威士兰
苏丹
苏里南
所罗门群岛
索马里
塔吉克斯坦
泰国
坦桑尼亚
汤加
特克斯和凯科斯群岛
特里斯坦-达库尼亚群岛
特立尼达和多巴哥
突尼斯
图瓦卢
土耳其
土库曼斯坦
托克劳
瓦利斯和富图纳
瓦努阿图
危地马拉
委内瑞拉
文莱
乌干达
乌克兰
乌拉圭
乌兹别克斯坦
希腊
西班牙
西撒哈拉
新加坡
新喀里多尼亚
新西兰
匈牙利
休达及梅利利亚
叙利亚
牙买加
亚美尼亚
也门
伊拉克
伊朗
以色列
意大利
印度
印度尼西亚
英国
英属维尔京群岛
英属印度洋领地
约旦
越南
赞比亚
泽西岛
乍得
直布罗陀
智利
中非共和国
*省份
*城市
*姓名
*电话
*单位
*职位
*邮箱
*请输入验证码
*验证码
B-hIL6/hIL6R mice
Strain Name C57BL/6-Il6tm1(IL6)Il6rtm2(IL6R)/Bcgen Common Name  B-hIL6/hIL6R mice
Background C57BL/6 Catalog number  120557
Related Genes 
IL6: CDF; HGF; HSF; BSF2; IL-6; BSF-2; IFNB2; IFN-beta-2
IL6R: IL6Q; gp80; CD126; IL6RA; IL6RQ; IL-6RA; IL-6R-1
NCBI Gene ID
16193,16194

mRNA expression analysis

from clipboard


Strain specific analysis of IL6 and IL6R gene expression in B-hIL6/hIL6R mice by RT-PCR. Mouse Il6 and Il6r mRNA were detectable in spleen of wild-type mice (+/+). Human IL6 was detectable only in homozygous B-hIL6/hIL6R mice (H/H) after stimulated with LPS for 3h. Human IL6R mRNA was detectable in homozygous B-hIL6/hIL6R mice but not in wild-type mice with or without LPS stimulation.


Protein expression analysis

from clipboard


Strain specific IL6 expression analysis in homozygous B-hIL6/hIL6R mice by ELISA. 
Serum were collected from WT (+/+) and homozygous B-hIL6/hIL6R (H/H) mice stimulated with LPS in vivo, and analyzed by ELISA with species-specific IL6 ELISA kit. Mouse Il6 was detectable in WT mice. Human IL6 was exclusively detectable in homozygous B-hIL6/hIL6R mice but not in WT mice.


Protein expression analysis

from clipboard

Strain specific IL6R expression analysis in homozygous B-hIL6/hIL6R mice by flow cytometry. Splenocytes were collected from WT (+/+) and homozygous B-hIL6/hIL6R mice (H/H), and analyzed by flow cytometry with species-specific anti-IL6R antibody. Mouse IL6R was detectable in WT mice. Human IL6R was exclusively detectable in homozygous B-hIL6/hIL6R mice but not in WT mice.


Analysis of spleen leukocytes cell subpopulations in B-hIL6/hIL6R mice


from clipboard



from clipboard


Analysis of spleen leukocyte subpopulations by FACS

Splenocytes were isolated from female C57BL/6 and B-hIL6/hIL6R mice (n=3, 6-week-old). Flow cytometry analysis of the splenocytes were performed to assess leukocyte subpopulations. (A) Representative FACS plots. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. (B) Results of FACS analysis. Percent of T cell, B cell, NK cell, monocyte, dendritic cell and macrophage in homozygous B-hIL6/hIL6R mice were similar to those in the C57BL/6 mice, demonstrating that IL6 and IL6R humanized does not change the overall development, differentiation or distribution of these cell types in spleen. Values are expressed as mean ± SEM.


Analysis of spleen T cell subpopulations in B-hIL6/hIL6R mice


from clipboard


Analysis of spleen T cell subpopulations by FACS
Splenocytes were isolated from female C57BL/6 and B-hIL6/hIL6R mice (n=3, 6-week-old).  Flow cytometry analysis of the splenocytes were performed to assess leukocyte subpopulations. (A) Representative FACS plots. Single live CD45+ cells were gated for CD3+ T cell population and used for further analysis as indicated here. (B) Results of FACS analysis. Percent of CD8+ T cell, CD4+ T cell, and Treg in homozygous B-hIL6/hIL6R mice were similar to those in the C57BL/6 mice, demonstrating that IL6 and IL6R humanized does not change the overall development, differentiation or distribution of these cell types in spleen. Values are expressed as mean ± SEM.

Analysis of lymph node leukocytes cell subpopulations in B-hIL6/hIL6R mice

from clipboard


Analysis of lymph node leukocyte subpopulations by FACS
Leukocytes were isolated from female C57BL/6 and B-hIL6/hIL6R mice (n=3, 6-week-old) Flow cytometry analysis of the leukocytes was performed to assess leukocyte subpopulations. (A) Representative FACS plots. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. (B)  Results of FACS analysis. Percent of T cell, B cell and NK cell in homozygous B-hIL6/hIL6R mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hIL6/hIL6R in place of its mouse counterpart does not change the overall development, differentiation or distribution of these cell types in lymph node. Values are expressed as mean ± SEM.

Analysis of lymph node T cell subpopulations in B-hIL6/hIL6R mice

from clipboard


Analysis of lymph node T cell subpopulations by FACS
Leukocytes were isolated from female C57BL/6 and B-hIL6/hIL6R mice (n=3, 6 week-old).  Flow cytometry analysis of the leukocytes was performed to assess leukocyte subpopulations. (A) Representative FACS plots. Single live CD45+ cells were gated for CD3 T cell population and used for further analysis as indicated here. (B) Results of FACS analysis. Percent of CD8+ cell, CD4+ cell, and Treg in homozygous B-hIL6/hIL6R mice were similar to those in the C57BL/6 mice, demonstrating that IL6 and IL6R humanized does not change the overall development, differentiation or distribution of these T cell subtypes in lymph node. Values are expressed as mean ± SEM.

In vivo efficacy of anti-human IL6 antibody

from clipboard

Efficacy of anti-human IL6 antibodies in B-hIL6/hIL6R mice with collagen induced arthritis (CIA) model. Mice in each group were treated with sirukumab (in house). Body weight change(A) and clinical score (B) were evaluated during treatment twice a week. There was no significant change in body weight, while total clinical score increased in the groups except control during days 21 to 28. It indicated that the arthritis mouse model had been constructed successfully. Clinical scores decreased in the two groups treated with sirukumab and dose-dependent. The results indicated the B-hIL6/hIL6R mice provide a powerful preclinical model for in vivo evaluation of anti-human IL6 antibodies.

In vivo efficacy of anti-human IL6 antibody


from clipboard

from clipboard


Efficacy of anti-human IL6 antibody in B-hIL6/hIL6R mice with collagen induced arthritis (CIA) model. Histopathological examination was performed on the joints of the extremities at endpoint. (A) Hematoxylin and eosin (H&E) staining. (B) Score of arthritis histology. G1 showed no significant abnormal changes. G2 showed bone structure damage(d), articular cavity or periarticular space disappeared (e), and pannus were observed (a), suggesting that the CIA model was successfully established. Compared with the G2 group, the low-dose group (G3) showed slight inflammatory cell infiltration (b) and pannus (a) and synovial hyperplasia (c). However, in the high dose group (G4), there was only partial pannus, the arthrosis disappeared and the articular cavity was obvious.